Sanara MedTech Inc.

NASDAQ:SMTI

Medical - Instruments & Supplies

Healthcare
$32.73 +3.44%

+$0.73 today

Market cap
$300.55M
Beta
1.19
P/E (TTM)
-5.7
EPS (TTM)
-$3.86
52W Low $16.05High $35.95

Volume 0.07M

Average 0.06M

SMTI Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Sanara MedTech Inc.NASDAQ: SMTI

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How SMTI compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Income tax expense amounts to 0.0% of revenue for SMTI, versus a peer median of 0.1%.
SMTI Competitors
Income Tax Expense for SMTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VMDViemed Healthcare, Inc.LTM Mar 2026$6.72M USD+29.3%+32.2%2.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$962K USD+199.0%—16.8%
HITIHigh Tide Inc.LTM Apr 2026CA$225.96K CAD-62.5%—0.0%
LFMDLifeMD, Inc.LTM Mar 2026$183.03K USD-54.5%-49.8%0.1%
XGNExagen Inc.LTM Mar 2026$87K USD+625.0%—0.1%
SMTISanara MedTech Inc.LTM Mar 2026$0 USD——0.0%
STXSStereotaxis, Inc.LTM Mar 2026$0 USD——0.0%
SGHTSight Sciences, Inc.LTM Mar 2026-$20K USD-107.7%-40.3%0.0%
NEONeoGenomics, Inc.LTM Jun 2026-$2.67M USD-89.0%—0.3%
TBRGTruBridge, Inc.LTM Mar 2026-$4.87M USD-129.5%—1.4%
Peer median (excluding SMTI) —-58.5%-40.3%0.1%

Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.14M45.84M64.99M86.67M103.12M
Cost of Revenue2.31M6.36M7.85M8.14M10.18M
Gross Profit21.83M39.48M57.14M78.53M92.94M
Gross Margin90.4%86.1%87.9%90.6%90.1%
Research & Development558.7K3.37M4.13M5.7M5.07M
Selling, General & Admin28.05M45.98M56.99M76.56M78.72M
Operating Expenses29.21M52M61.35M85.25M83.79M
Depreciation & Amortization771.93K2.37M3.68M4.92M2.66M
EBITDA(7.22M)(11.57M)(289.1K)(1.86M)9.03M
EBITDA Margin-29.9%-25.2%-0.4%-2.1%8.8%
Operating Income(7.38M)(12.52M)(4.22M)(6.72M)9.15M
Operating Margin-30.6%-27.3%-6.5%-7.7%8.9%
Interest Income0284.75K021.98K3.67K
Interest Expense711284.75K475.78K3.13M6.76M
Other Income / Expenses(617.64K)(1.42M)(224.75K)(3.2M)(9.54M)
Income Before Tax(7.99M)(13.94M)(4.44M)(9.91M)(393.12K)
Pre-Tax Margin-33.1%-30.4%-6.8%-11.4%-0.4%
Income Tax Expense0(5.84M)000
Net Income(7.92M)(7.94M)(4.3M)(9.66M)(37.56M)
Net Margin-32.8%-17.3%-6.6%-11.2%-36.4%
EPS (Basic)(1.08)(1.00)(0.52)(1.14)(4.36)
EPS (Diluted)(1.08)(1.00)(0.52)(1.14)(4.36)
Weighted Avg Shares7.34M7.91M8.28M8.48M8.62M
Weighted Avg Shares (Diluted)7.34M7.91M8.28M8.48M8.62M

Sanara MedTech Inc.

NASDAQ:SMTI

Intrinsic Alpha fair value

Locked

Current Price

$32.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.